FY2025 · ended Dec 31, 2025 · Revenue $2.53B, +20.0% YoY · Filed Feb 10, 2026
Medpace Holdings, Inc. (MEDP) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.5 billion and net income of $451.1 million. Free cash flow was $681.9 million. As of Sep 30, 2026 it held $705.3 million in cash and investments and $171.5 million in total debt.
Revenue (TTM)
$2.84B
+20.4% vs year-ago TTM
Net income (TTM)
$517.83M
+19.6% vs year-ago TTM
Operating cash flow (TTM)
$723.05M
+1.7% vs year-ago TTM
Free cash flow (TTM)
$667.63M
-1.4% vs year-ago TTM
EPS (TTM)
$18.03
+26.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
28.38M
-6.8% vs prior year
Net cash
$533.86M
as of Sep 30, 2026
Operating margin
21.4%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MEDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cincinnati, OH
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1668397
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.5B | $2.1B | $1.9B | $1.5B | $1.1B |
| Operating income | $534.9M | $446.9M | $336.8M | $278.7M | $198.6M |
| Net income | $451.1M | $404.4M | $282.8M | $245.4M | $181.8M |
| Diluted EPS | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 |
| Operating cash flow | $713.2M | $608.8M | $433.4M | $388.1M | $263.3M |
| Free cash flow | $681.9M | $572.3M | $396.7M | $351.2M | $235.1M |
| Total assets | $2.0B | $2.1B | $1.7B | $1.4B | $1.7B |
| Total liabilities | $1.5B | $1.3B | $1.1B | $966.1M | $707.0M |
| Stockholders' equity | $459.1M | $825.5M | $559.0M | $386.4M | $952.9M |
| Cash and investments | $497.0M | $669.4M | $245.4M | $28.3M | $461.3M |
| Total debt | $136.9M | $149.5M | $164.5M | $208.1M | $147.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 22, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 4, 2026 | Jun 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 19, 2026 | May 15, 2026 |
All 930 Medpace Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.